New Risk • Jun 01
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Hong Kong stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 75% per year over the past 5 years. Announcement • May 12
Jinhai Medical Technology Limited, Annual General Meeting, Jun 15, 2026 Jinhai Medical Technology Limited, Annual General Meeting, Jun 15, 2026, at 15:00 China Standard Time. Location: 3rd floor, block east, 1275 meichuan road, putuo district, shanghai, china, China New Risk • Apr 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 75% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (11% average weekly change). Reported Earnings • Mar 28
Full year 2025 earnings released: S$0.003 loss per share (vs S$0.003 loss in FY 2024) Full year 2025 results: S$0.003 loss per share (in line with FY 2024). Revenue: S$46.3m (down 7.9% from FY 2024). Net loss: S$17.1m (loss narrowed 4.9% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 132 percentage points per year, which is a significant difference in performance. Announcement • Mar 13
Jinhai Medical Technology Limited to Report Fiscal Year 2025 Results on Mar 27, 2026 Jinhai Medical Technology Limited announced that they will report fiscal year 2025 results on Mar 27, 2026 Reported Earnings • Sep 01
First half 2025 earnings released: S$0.002 loss per share (vs S$0.001 loss in 1H 2024) First half 2025 results: S$0.002 loss per share (further deteriorated from S$0.001 loss in 1H 2024). Revenue: S$14.5m (down 44% from 1H 2024). Net loss: S$10.3m (loss widened 70% from 1H 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 110 percentage points per year, which is a significant difference in performance. Announcement • Aug 15
Jinhai Medical Technology Limited to Report First Half, 2025 Results on Aug 29, 2025 Jinhai Medical Technology Limited announced that they will report first half, 2025 results on Aug 29, 2025 New Risk • Aug 15
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Hong Kong stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 84% per year over the past 5 years. Announcement • May 23
Jinhai Medical Technology Limited, Annual General Meeting, Jun 25, 2025 Jinhai Medical Technology Limited, Annual General Meeting, Jun 25, 2025, at 15:00 China Standard Time. Location: 3rd floor, block east, 1275 meichuan road, putuo district, shanghai., China Reported Earnings • Apr 30
Full year 2024 earnings released: S$0.003 loss per share (vs S$0.001 loss in FY 2023) Full year 2024 results: S$0.003 loss per share (further deteriorated from S$0.001 loss in FY 2023). Revenue: S$50.2m (up 10% from FY 2023). Net loss: S$18.0m (loss widened 472% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 163 percentage points per year, which is a significant difference in performance. Reported Earnings • Mar 30
Full year 2024 earnings released: S$0.003 loss per share (vs S$0.001 loss in FY 2023) Full year 2024 results: S$0.003 loss per share (further deteriorated from S$0.001 loss in FY 2023). Revenue: S$50.2m (up 10% from FY 2023). Net loss: S$18.0m (loss widened 472% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 162 percentage points per year, which is a significant difference in performance. Announcement • Mar 21
Jinhai Medical Technology Limited Provides Group Earnings Guidance for the Year Ended December 31, 2024 Jinhai Medical Technology Limited provided group earnings guidance for the year ended December 31, 2024. The board of directors of the Company informed the shareholders of the Company and potential investors that, based on a preliminary review of the unaudited consolidated management accounts of the Group for the year ended 31 December 2024 ("FY2024") and other information currently available to the Board, the Group is expected to record a loss after taxation of approximately SGD 18.1 million as compared to a loss after taxation for year ended 31 December 2023 ("FY2023") of approximately SGD 4.1 million. Based on the unaudited consolidated management accounts of the Group for FY2024, the Board considered that the business of the Group demonstrated a steady development during FY2024. The Group expected to record revenue of approximately SGD 50.2 million for FY2024, as compared to revenue of approximately SGD 45.6 million for FY2023. The increase in net loss position for FY2024 was principally attributable to, amongst others, the increase in administrative expenses by approximately SGD 15.9 million, primarily resulting from the incurrence of expenses on equity-settled share-based payments in the amount of approximately SGD 13.3 million for FY2024, as a result of grant of share options to certain employees of the Group during FY2024 (FY2023: nil). Announcement • Mar 14
Jinhai Medical Technology Limited to Report Fiscal Year 2024 Results on Mar 28, 2025 Jinhai Medical Technology Limited announced that they will report fiscal year 2024 results on Mar 28, 2025 Announcement • Jan 28
Jinhai Medical Technology Limited Announces Board Changes Jinhai Medical Technology Limited appointed Mr. Jiang Jiangyu as a non-executive director of the Company ("Director") with effect from 28 January 2025. Mr. Jiang is also appointed as the vice chairman of the Board. Mr. Jiang Jiangyu (" Mr. Jiang "), Aged 42, Has Extensive Experience in the Information Technology Industry and Business Management. Mr. Jiang Obtained A Bachelor's Degree in Administration At the Huazhong University of Science and Technology in June 2006. Mr. Jiang Also Graduated from the Shanghai Advanced Institute of Finance of the Shanghai Jiao Tong University with A Master's Degree in Executive Business Administration in June 2018. from August 2010 to April 2012, Mr. Jiang Worked At the Sales Department of Trend Micro (China) Incorporated. from June 2012 to February 2014, Mr. Jiang Worked as A Deputy Director of Sales of the Eastern China Region of Kaspersky Technology Development (Beijing) Co. Ltd. (Shanghai Branch). from July 2014 to December 2017, Mr. Jiang Worked as A President of Shanghai Lucai Internet Technology Company Limited. Since January 2018, Mr. Jiang Has Been A President of Shanghai Shunma Data Technology Company Limited. Mr. Jiang Has Also Been A Non-Executive Director and A Member of the Remuneration Committee of the Company from 19 July 2019 to 6 August 2021. Mr. Jiang Served as the Deputy Secretary General of Shanghai Information Security Trade Association from 2013 to 2016 and Is Currently the Deputy Chairman of Ningbo Chamber of Commerce in Shanghai. Since December 2018, Mr. Jiang Has Been A Deputy Chairman of the Information Technology Chamber of Commerce of Shanghai Federation of Industry and Commerce. The Board further announced that Mr. Dai Yong ("Mr. Dai") has tendered his resignation as an executive Director with effect from 28 January 2025 due to his other business commitments which require more of his time and dedication. Immediately upon the taking effect of his resignation, Mr. Dai also resigned as the chief operation officer of the Group. New Risk • Jan 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 59% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (13% average weekly change). Board Change • Jan 01
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 7 experienced directors. No highly experienced directors. 3 independent directors (5 non-independent directors). Independent Non-Executive Director Meihua Yang was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Oct 05
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Meihua Yang was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Aug 21
Jinhai Medical Technology Limited Provides Earnings Guidance for the Six Months Ended 30 June 2024 The board of directors of Jinhai Medical Technology Limited informed shareholders of the Company and potential investors that, based on a preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2024 and other information currently available to the Board, the Group is expected to record a loss after taxation of approximately SGD 6.0 million as compared to a profit after taxation for the six month ended 30 June 2023 of approximately SGD 590,000. Based on the unaudited consolidated management accounts of the Group for 1H2024, the Board considered that the business of the Group showed a positive development during 1H2024. The Group recorded revenue of approximately SGD 25.9 million and gross profit of approximately SGD 7.4 million for 1H2024, which represented a positive improvement as compared to revenue of approximately SGD 12.0 million and gross profit of approximately SGD 5.0 million for 1H2023. The turnaround from net profit position for 1H2023 to the net loss position for 1H2024 was principally attributable to, amongst others, the incurrence of expenses on equity-settled share-based payments in the amount of approximately SGD 6.5 million, as a result of grant of share options to certain employees of the Group during 1H2024 (1H2023: nil). Announcement • Aug 20
Jinhai Medical Technology Limited to Report First Half, 2024 Results on Aug 30, 2024 Jinhai Medical Technology Limited announced that they will report first half, 2024 results on Aug 30, 2024 Announcement • May 26
Jinhai Medical Technology Limited, Annual General Meeting, Jun 26, 2024 Jinhai Medical Technology Limited, Annual General Meeting, Jun 26, 2024, at 15:00 China Standard Time. Location: block 3 east, 1275 meichuan road, putuo district, shanghai China Reported Earnings • Mar 29
Full year 2023 earnings released: S$0.002 loss per share (vs S$0 in FY 2022) Full year 2023 results: S$0.002 loss per share (further deteriorated from S$0 in FY 2022). Revenue: S$45.6m (up 105% from FY 2022). Net loss: S$3.14m (down S$3.61m from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 141 percentage points per year, which is a significant difference in performance. Announcement • Mar 16
Jinhai Medical Technology Limited to Report Fiscal Year 2023 Results on Mar 27, 2024 Jinhai Medical Technology Limited announced that they will report fiscal year 2023 results on Mar 27, 2024 Announcement • Mar 15
Jinhai Medical Technology Limited Announces Resignation of Sze Chin Pei Pacita as Company Secretary Jinhai Medical Technology Limited announced that Ms. Sze Chin Pei Pacita has resigned as the company secretary of the Company and one of the two authorized representatives of the Company for accepting service of process and notices on behalf of the Company in Hong Kong under Part 16 of the Companies Ordinance with effect from 14 March 2024. The Company is in the process of identifying a suitable candidate to fill the vacancy in the office of Company Secretary caused by the resignation of Ms. Sze, and will publish further announcement once such appointment is confirmed. Announcement • Jan 10
Jinhai International Group Holdings Limited Appoints Mr. Liu Lei as Chief Technical Officer Jinhai International Group Holdings Limited announced that Mr. Liu Lei a director and the general manager of Shanghai Jinhai Medical Technology Co. Ltd. appointed as chief technical officer of the Group with effect from 1 December 2023 for an initial term of three years, primarily responsible for obtaining certification for and the research and development of Jinhai Medical 's products, and overseeing the implementation of other new products and new technologies to make sure that they will be in line with the Group's long-term development strategy. Mr. Liu, aged 35, graduated from the School of Health Science and Engineering USSR (formerly known as School of Medical Instrument and Food Engineering USST ("School of Health Science") with a bachelor degree specialising in pharmacy and has obtained a professional diploma in International Economics and Trade at Fudan University. Mr. Liu was a student under Dr. Song Chengli a specialist in minimally invasive surgery at the School of Health Science, and has worked mainly on product development at various international medical and surgical equipment companies in aggregate for over 10 years, including (i) B. Braun Medical (Shanghai) International Trading Co. Ltd. (ii) Stryker (Beijing) Healthcare Products Company Limited Shanghai branch ("Stryker"), a subsidiary of Stryker Corporation and listed on Nasdaq, where he was awarded the 2012 Asia-Pacific Elite Award during his tenure at Stryker, (iii) Shenzhen Mindray Bio-Medical Electronics Co. Ltd. where he participated in the establishment of its minimally invasive surgery division, and (iv) Suzhou Teresa Intelligent Technology Co. Ltd. where he served as marketing and sales director. One of STLS's shareholders, Suzhou Caring Medical Co., Ltd, is a company that obtained the PRC's first fluorescence endoscope registration certificate. Mr. Liu subsequently served as chief executive officer of Shanghai RayLau Technologies Co. Ltd. Mr. Liu founded the non-profit industry platform " Minimally Invasive Surgery Industry Observation in February 2019 to promote the industry and strengthen the connections within the industry. Mr. Liu has been the editor for the publication of more than 30 industry observation reports and research reports. He has also co-hosted with Dr. Song Chengli of the "China Minimally Invasive Medical Devices (Tonglu) Summit Forum. Mr. Liu was the initiator of more than 35 patents applications for Jinhai Medical and Jinhai Medical has been granted licence for over 30 patents in aggregate under the supervision of Mr. Liu. Announcement • Dec 29
Jinhai International Group Holdings Limited Change of Company Secretary, Effective from 1 January 2024 The board of directors of Jinhai International Group Holdings Limited announced that Mr. Wong Man Yiu has resigned, with effect from 1 January 2024, as (i) the company secretary of the Company, (ii) one of the authorised representatives of the Company as required under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and (iii) the process agent of the Company for accepting service of process or notices on behalf of the Company in Hong Kong under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong). Mr. Wong has confirmed to the Board that he has no disagreement with the Board and there are no matters relating to his resignations that need to be brought to the attention of the Stock Exchange and the shareholders of the Company. The Board announced that Ms. Sze Chin Pei Pacita has been appointed as the Company Secretary, an Authorised Representative and the Process Agent with effect from 1 January 2024 to fill the vacancy following Mr. Wong's resignation. Ms. Sze has over 20 years of experience in finance, accounting and listed company matters. Ms. Sze obtained a Master of Business Administration degree from University of Warwick, the United Kingdom and a Master of Law (International Corporate Finance) from University of Law, United Kingdom. She is a chartered accountant of Institute of Chartered Accountants in England and Wales, a fellow of the Association of Chartered and Certified Accountants in the United Kingdom and a fellow of the Hong Kong Institute of Certified Public Accountants in Hong Kong. New Risk • Nov 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.02% net profit margin). Shareholders have been diluted in the past year (5.1% increase in shares outstanding). New Risk • Oct 19
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.02% net profit margin). Shareholders have been diluted in the past year (5.1% increase in shares outstanding). Reported Earnings • Sep 01
First half 2023 earnings released: EPS: S$0.001 (vs S$0.001 in 1H 2022) First half 2023 results: EPS: S$0.001 (in line with 1H 2022). Revenue: S$12.0m (down 19% from 1H 2022). Net income: S$938.7k (down 30% from 1H 2022). Profit margin: 7.8% (down from 9.1% in 1H 2022). Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings. New Risk • Aug 31
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.02% Last year net profit margin: 1.4% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.02% net profit margin). Announcement • Aug 01
Jinhai International Group Holdings Limited Announces Board Changes The board of directors of the company of Jinhai International Group Holdings Limited announced that Mr. Yu Mingyang has been appointed as non-executive Director with effect from 31 July 2023. Mr. Yu Mingyang, aged 59, has extensive experience in branding strategy and management. Mr. Yu served as an independent non-executive director of Noble Jewelry Holdings Limited, a company listed on the Stock Exchange and currently known as Central Development Holdings Limited, from January 1994 to January 2002; and as an independent director of Zoneco Group Co. Ltd., a company listed on the Shenzhen Stock Exchange, from June 2007 to June 2010. Mr. Yu also served as an independent director of Shandong Homey Aquatic Development Co. Ltd.,a company listed on the Shanghai Stock Exchange, from March 2011 to May 2015; and as an independent non-executive director of Carpenter Tan Holdings Limited, a company listed on the Stock Exchange, from September 2007 to January 2016. Mr. Yu has served as a professor at Shanghai Jiao Tong University since September 2005. He has been (i) an independent director of Shanghai Xujiahui Commercial Co. Ltd., a company listed on the Shenzhen Stock Exchange, since March 2018; (ii) an independent director of Golden Home Living Co. Ltd., a company listed on the Shanghai Stock Exchange, since September 2019, and (iii) an independent non-executive director of MedSci Healthcare Holdings Limited, a company listed on the Stock Exchange, since April 2023. Mr. Yu obtained his bachelor's degree in philosophy from Hangzhou University in the PRC in July 1983. Mr. Yu obtained a master's degree and a doctor's degree in management from Fudan University in the PRC in July 1993 and July 1996, respectively. The Board announced that Mr. Li Yunping has been redesignated from a non-executive Director to an executive Director with effect from 31 July 2023. Mr. Li Yunping ("Mr. Li"), aged 69, had approximately 35 years of experience in the banking industry. Mr. Li held various positions in Ningbo Beilun Rural Commercial Bank Company Limited from May 1979 to January 2014. From May 1981 to September 1986, Mr. Li was a supervisor at Beilun Lianshe Jiangnan Credit Union and from September 1986 to February 2000, Mr. Li was a supervisor at Beilun Lianshe Xiaogang Credit Union . His last position at Ningbo Beilun Rural Commercial Bank Company Limited was a senior economist from October 1995 until January 2014. Announcement • Jul 29
Jinhai International Group Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023 Jinhai International Group Holdings Limited announced that they will report first half, 2023 results on Aug 30, 2023 Announcement • May 24
Jinhai International Group Holdings Limited, Annual General Meeting, Jun 28, 2023 Jinhai International Group Holdings Limited, Annual General Meeting, Jun 28, 2023, at 15:00 China Standard Time. Location: Block 3 East, 1275 Meichuan Road Putuo District Shanghai Province China Agenda: To consider, receive and adopt the audited consolidated financial statements and the report of the directors and the independent auditor's report of the Company for the year ended 31 December 2022; to consider the executive change; to authorize the board of directors of the Company to fix the remunerations of the directors of the Company; to re-appoint HLB Hodgson Impey Cheng Limited as auditor of the Company and authorize the board of directors of the Company to fix its remuneration; and to consider the other resolutions. Reported Earnings • Apr 01
Full year 2022 earnings released: EPS: S$0 (vs S$0 in FY 2021) Full year 2022 results: EPS: S$0 (in line with FY 2021). Revenue: S$22.3m (up 4.0% from FY 2021). Net income: S$468.1k (up S$680.1k from FY 2021). Profit margin: 2.1% (up from net loss in FY 2021). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth. Announcement • Feb 18
Jinhai International Group Holdings Limited to Report Fiscal Year 2022 Results on Mar 30, 2023 Jinhai International Group Holdings Limited announced that they will report fiscal year 2022 results on Mar 30, 2023 Board Change • Nov 16
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Director Meihua Yang was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Sep 01
First half 2022 earnings released: EPS: S$0.001 (vs S$0.001 in 1H 2021) First half 2022 results: EPS: S$0.001 (vs S$0.001 in 1H 2021). Revenue: S$14.7m (up 53% from 1H 2021). Net income: S$1.40m (up 90% from 1H 2021). Profit margin: 9.5% (up from 7.6% in 1H 2021). Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Announcement • Jul 30
Jinhai International Group Holdings Limited Announces Board Changes Jinhai International Group Holdings Limited announces that Mr. Yang Fu Kang has tendered his resignation as a non-executive Director with effect from 29 July 2022 due to his other business commitments which require more of his time and dedication. Immediately upon the taking effect of his resignation, Mr. Yang shall also cease to be the deputy chairman of the Board and a member of the audit committee of the Board. Announcement • Jul 28
Jinhai International Group Holdings Limited to Report First Half, 2022 Results on Aug 30, 2022 Jinhai International Group Holdings Limited announced that they will report first half, 2022 results on Aug 30, 2022 Announcement • May 27
Jinhai International Group Holdings Limited, Annual General Meeting, Jun 28, 2022 Jinhai International Group Holdings Limited, Annual General Meeting, Jun 28, 2022, at 15:00 China Standard Time. Location: Block 3 East, 1275 Meichuan Road,Putuo District, Shanghai Shanghai Province China Agenda: To consider, receive and adopt the audited consolidated financial statements and the report of the directors and the independent auditor's report of the Company for the year ended 31 December 2021; to consider and approve to re-elect directors; to re-appoint Foo Kon Tan LLP as auditor of the Company and authorize the board of directors of the Company to fix its remuneration; and to consider other matters. Board Change • Apr 27
Less than half of directors are independent There are 8 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. 3 independent directors (5 non-independent directors). Independent Non-Executive Director Yimin Fan is the most experienced director on the board, commencing their role in 2019. Independent Non-Executive Director Meihua Yang was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Reported Earnings • Apr 01
Full year 2021 earnings released: EPS: S$0 (vs S$0.001 in FY 2020) Full year 2021 results: EPS: S$0 (down from S$0.001 in FY 2020). Revenue: S$21.4m (down 4.7% from FY 2020). Net loss: S$269.4k (down 121% from profit in FY 2020). Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Announcement • Mar 30
Jinhai International Group Holdings Limited Announces Earnings Guidance for the Year Ended 31 December 2021 Jinhai International Group Holdings Limited announced earnings guidance for the year ended 31 December 2021. The Group is expected to record a loss after taxation for 2021 of approximately SGD 0.10 million as compared to a profit after taxation for the year ended 31 December 2020 of approximately SGD 1.26 million. Announcement • Feb 01
Jinhai International Group Holdings Limited Announces Executive Changes Jinhai International Group Holdings Limited announce that Ms. Yang Meihua has been appointed as independent non-executive Director of the Company with effect from 31 January 2022. Ms. Yang Meihua, aged 62, has extensive experience in the field of accounting and finance. Ms Yang is a member of the Chinese Institute of Certified Public Accountants. Ms. Yang received her undergraduate diploma from Fudan University, the PRC. She worked at Arthur Andersen Hua Qiang Certified Public Accountants Shanghai Office from 1 October 1995 to 30 June 2002 and PricewaterhouseCoopers Zhong Tian Certified Public Accountants from 1 July 2002 to 25 March 2003. Ms. Yang has been working at Shanghai Nortex Certified Public Accountants Co. Ltd., since April 2004. There is a one-year service contract entered into between the Company and Ms. Yang who is subject to retirement by rotation and re-election at annual general meetings of the Company in accordance with the Articles of Association of the Company. Ms. Yang will receive a fixed director's fee of HK$120,000 per annum. Her remuneration is determined by the Board with reference to her roles and responsibilities with the Company and prevailing market conditions. The Board announces that Mr. Chai Chi Man has resigned as independent non-executive Director of the Company due to his other business commitments which require more of his time and dedication. Mr. Chai has confirmed to the Board that he has no disagreement with the Board and that there are no other matters in relation to his resignation that need to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited. With effect from 31 January 2022, the composition of the Board committees has been changed as follows: Ms. Yang has been appointed as a member of the Audit Committee of the Company with effect from 31 January 2022 while Mr. Chai has resigned as a member of the Audit Committee with effect from 31 January 2022. Ms. Yang has been appointed as a member of the Nomination Committee of the Company with effect from 31 January 2022 while Mr. Chai has resigned as a member of the Nomination Committee with effect from 31 January 2022. Ms. Yang has been appointed as a member of the Remuneration Committee of the Company with effect from 31 January 2022 while Mr. Chai has resigned as a member of the Remuneration Committee with effect from 31 January 2022. Reported Earnings • Sep 03
First half 2021 earnings released: EPS S$0.001 (vs S$0.001 in 1H 2020) The company reported a poor first half result with weaker earnings, revenues and profit margins. First half 2021 results: Revenue: S$9.65m (down 30% from 1H 2020). Net income: S$737.1k (down 36% from 1H 2020). Profit margin: 7.6% (down from 8.3% in 1H 2020). Over the last 3 years on average, earnings per share has increased by 100% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth. Executive Departure • Aug 10
Non-Executive Director Jiangyu Jiang has left the company On the 6th of August, Jiangyu Jiang's tenure as Non-Executive Director ended after 2.1 years in the role. We don't have any record of a personal shareholding under Jiangyu's name. Jiangyu is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 2.08 years. Reported Earnings • Apr 01
Full year 2020 earnings released: EPS S$0.001 (vs S$0.001 loss in FY 2019) The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: S$22.5m (down 57% from FY 2019). Net income: S$1.26m (up S$1.95m from FY 2019). Profit margin: 5.6% (up from net loss in FY 2019). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Announcement • Mar 21
Jinhai International Group Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 December 2020 Jinhai International Group Holdings Limited provided unaudited consolidated earnings guidance for the year ended 31 December 2020. For the period, the Group is expected to record a profit after taxation of not less than SGD 1.8 million as compared to a loss after taxation for the year ended 31 December 2019 of approximately SGD 0.7 million. Announcement • Mar 09
Jinhai International Group Holdings Limited to Report Fiscal Year 2020 Results on Mar 30, 2021 Jinhai International Group Holdings Limited announced that they will report fiscal year 2020 results on Mar 30, 2021 Is New 90 Day High Low • Feb 26
New 90-day high: HK$1.52 The company is up 13% from its price of HK$1.34 on 27 November 2020. The Hong Kong market is also up 13% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Professional Services industry, which is flat over the same period. Is New 90 Day High Low • Jan 15
New 90-day high: HK$1.50 The company is up 11% from its price of HK$1.35 on 16 October 2020. The Hong Kong market is up 15% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Professional Services industry, which is down 21% over the same period. Is New 90 Day High Low • Dec 04
New 90-day low: HK$1.19 The company is down 20% from its price of HK$1.49 on 04 September 2020. The Hong Kong market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Professional Services industry, which is down 14% over the same period. Reported Earnings • Sep 27
First half earnings released Over the last 12 months the company has reported total losses of S$231.4k, with losses narrowing by 85% from the prior year. Total revenue was S$40.4m over the last 12 months, down 21% from the prior year. Is New 90 Day High Low • Sep 22
New 90-day high: HK$1.54 The company is up 11% from its price of HK$1.39 on 24 June 2020. The Hong Kong market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Professional Services industry, which is down 2.0% over the same period. Announcement • Aug 22
Jinhai International Group Holdings Limited to Report First Half, 2020 Results on Aug 25, 2020 Jinhai International Group Holdings Limited announced that they will report first half, 2020 results on Aug 25, 2020 